Description: Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Home Page: brightmindsbio.com
DRUG Technical Analysis
1500 – 1055 West Georgia Street
Vancouver,
BC
V6E 4N7
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Ian McDonald | Co-Founder, CEO, Pres & Director |
| Mr. Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer |
| Dr. Emer Leahy M.B.A., Ph.D. | Consultant |
| Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Interim Chief Science Officer & Director |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
| Dr. Gideon Shapiro Ph.D. | VP of Discovery |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7138 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-03-22 |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |